Best of the Week
Most Popular
1. Market Decline Will Lead To Pension Collapse, USD Devaluation, And NWO - Raymond_Matison
2.Uber’s Nightmare Has Just Started - Stephen_McBride
3.Stock Market Crash Black Swan Event Set Up Sept 12th? - Brad_Gudgeon
4.GDow Stock Market Trend Forecast Update - Nadeem_Walayat
5.Gold Significant Correction Has Started - Clive_Maund
6.British Pound GBP vs Brexit Chaos Timeline - Nadeem_Walayat
7.Cameco Crash, Uranium Sector Won’t Catch a break - Richard_Mills
8.Recession 2020 Forecast : The New Risks & New Profits Of A Grand Experiment - Dan_Amerman
9.Gold When Global Insanity Prevails - Michael Ballanger
10.UK General Election Forecast 2019 - Betting Market Odds - Nadeem_Walayat
Last 7 days
Gold Price Breaks Down, Waving Good-bye to the 2019 Rally - 12th Nov 19
Fed Can't See the Bubbles Through the Lather - 12th Nov 19
Double 11 Record Sales Signal Strength of Chinese Consumption - 12th Nov 19
Welcome to the Zombie-land Of Oil, Gold and Stocks Investing – Part II - 12th Nov 19
Gold Retest Coming - 12th Nov 19
New Evidence Futures Markets Are Built for Manipulation - 12th Nov 19
Next 5 Year Future Proof Gaming PC Build Spec November 2019 - Ryzen 9 3900x, RTX 2080Ti... - 12th Nov 19
Gold and Silver - The Two Horsemen - 11th Nov 19
Towards a Diverging BRIC Future - 11th Nov 19
Welcome to the Zombie-land Of Stock Market Investing - 11th Nov 19
Illiquidity & Gold And Silver In The End Game - 11th Nov 19
Key Things You Need to Know When Starting a Business - 11th Nov 19
Stock Market Cycles Peaking - 11th Nov 19
Avoid Emotional Investing in Cryptocurrency - 11th Nov 19
Australian Lithium Mines NOT Viable at Current Prices - 10th Nov 19
The 10 Highest Paying Jobs In Oil & Gas - 10th Nov 19
World's Major Gold Miners Target Copper Porphyries - 10th Nov 19
AMAZON NOVEMBER 2019 BARGAIN PRICES - WD My Book 8TB External Drive for £126 - 10th Nov 19
Gold & Silver to Head Dramatically Higher, Mirroring Palladium - 9th Nov 19
How Do YOU Know the Direction of a Market's Larger Trend? - 9th Nov 19
BEST Amazon SMART Scale To Aid Weight Loss for Christmas 2019 - 9th Nov 19
Why Every Investor Should Invest in Water - 8th Nov 19
Wait… Was That a Bullish Silver Reversal? - 8th Nov 19
Gold, Silver and Copper The 3 Metallic Amigos and the Macro Message - 8th Nov 19
Is China locking up Indonesian Nickel? - 8th Nov 19
Where is the Top for Natural Gas? - 7th Nov 19
Why Fractional Shares Don’t Make Sense - 7th Nov 19
The Fed Is Chasing Its Own Tail; It Doesn’t Care What You Think - 7th Nov 19
China’s path from World’s Factory to World Market - 7th Nov 19
Where Is That Confounded Recession? - 7th Nov 19
FREE eBook - The Investment Strategy that could change your future - 7th Nov 19
Is There a Stock Market Breakout Ahead? - 6th Nov 19
These Indicators Aren’t Putting to an Economic Resurgence - 6th Nov 19
Understanding the Different Types of Travel Insurance - 6th Nov 19
The Biggest Gold Story Of 2020 - 6th Nov 19
Best Money Saving FREE Bonfire Night Fire Works Show Sheffield 2019 - 5th Nov 19
Is the Run on the US Dollar Due to Panic or Greed? - 5th Nov 19
Reasons Why Madrid Attracts Young Professionals - 5th Nov 19
Larger Bullish Move in USD/JPY May Just Be Getting Started - 5th Nov 19
Constructive Action in Gold & Silver Stocks - 5th Nov 19
The Boring Industry That Hands +500% Gains - 5th Nov 19
Stock Market Chartology vs Fundamentals - 4th Nov 19
The Fed’s Policy Is Like Swatting Flies with Nuclear Weapons - 4th Nov 19
Stock Market Warning: US Credit Delinquencies To Skyrocket In Q4 - 4th Nov 19
Stock Market Intermediate Topping Process Continues - 4th Nov 19
Stock Market $SPY Expanded Flat, Déjà Vu All Over Again - 4th Nov 19
How To Buy Gold For $3 An Ounce - 4th Nov 19

Market Oracle FREE Newsletter

Category: BioTech

The analysis published under this category are as follows.

Companies

Thursday, August 07, 2014

New Growth Ideas for Biotech Stock Investors / Companies / BioTech

By: TLSReport

Medical technology is intimately linked to regenerative medicine. You could say these industries have a thunder-and-lightning relationship—you can't have one without the other. Mark Landy, director of research for medical technology and regenerative medicine at Summer Street Research Partners, has staked out the intertwined sectors as his universe of coverage. In this interview with The Life Sciences Report, Landy discusses three companies with very distinct capabilities that could bring extraordinary rewards to investors who understand the value propositions.

Read full article... Read full article...

 


Companies

Friday, August 01, 2014

Turning a Clinical Eye on Biotech Stocks with High Potential Investor Reward / Companies / BioTech

By: TLSReport

A biotech analyst could play it safe, and stick with mid-, late- and commercial-stage companies that offer higher odds and decent returns on good news. Christopher James, on the other hand, recommends that investors willing to diversify their holdings and take on informed risk hold a short list of companies with huge potential. James, a senior analyst and managing director at Brinson Patrick Securities, is a neurosurgeon by training, and examines new platforms and proposed therapies with a clinician's eye. In this interview with The Life Sciences Report, James turns that eye on three names with dramatic, paradigm-changing technology platforms that could energize portfolios.

Read full article... Read full article...

 


Companies

Wednesday, July 02, 2014

The BioScience Stocks Profit Outlook for the Rest of 2014 / Companies / BioTech

By: Money_Morning

Ernie Tremblay writes: With just six months left on my 2014 bioscience "profit calendar," things are really starting to look promising for the second half of 2014. There are huge opportunities in several subsectors of the bioscience market in particular.

That said, some bioscience analysts are saying there's a bubble. And it's scaring a lot of bioscience investors out of great positions in the market.

That's why last week I shared my complete bioscience market outlook for the rest of 2014 with my paid members - to help them see the real market story.

Read full article... Read full article...

 


Companies

Monday, June 30, 2014

How to Tap Big Profits in That "Other" Bioscience Niche / Companies / BioTech

By: Money_Morning

Ernie Tremblay writes: At first glance, it may seem like bioscience investing is so complicated and risky that it's hardly worth your time and money to invest, at least if you don't have someone knowledgeable to guide you.

And it's true. Putting your money behind new, experimental drugs, without some guidance, is a crapshoot.

But there's an approach to making profits from this sector that doesn't rely on breakthrough discoveries, expensive drug trials, or constant cash infusions through dilutive public offerings to fuel its engine.

Read full article... Read full article...

 


Companies

Wednesday, June 18, 2014

Not Even Washington's Meddling Could Stop Biotech’s Biggest Comeback / Companies / BioTech

By: Money_Morning

Michael A. Robinson writes: Late last month, I told you that biotech is one of the best ways to profit from the tech rebound. In fact, it was my “No Doz Opportunity No. 1.”

Somewhat ironically, a rollover in the biotech market was one of the proximate causes of the overall selloff in tech earlier this year.

And now I’m recommending that you invest in the company that purportedly “caused” the biotech market to roll over in the first place.

Read full article... Read full article...

 


Companies

Tuesday, June 10, 2014

Profit From the "Scariest Event" in Bioscience / Companies / BioTech

By: Money_Morning

Ernie Tremblay writes: In bioscience investing, binary catalysts are milestone events that signal a thumbs-up or thumbs-down for an experimental drug as it makes its way through the regulatory process.

Positive catalysts can send a share price soaring. Negative ones can send it into a nosedive.

Perhaps the least understood of these catalysts are FDA Advisory Committee (a.k.a. AdCom) recommendations.

Read full article... Read full article...

 


Companies

Saturday, May 24, 2014

Healing the Blind… and Boosting Your Stocks Portfolio / Companies / BioTech

By: Casey_Research

By Chris Wood, Senior Analyst

Vision is one of the most important elements of our life, if not the most important one. A 2010 survey by Surge Research found that 60% of Americans are more afraid of blindness than of heart disease, the primary killer of both men and women in the United States.

Read full article... Read full article...

 


Companies

Friday, May 23, 2014

Four Telltale Signs of a Bioscience "Blockbuster" Biotech Stock in the Making / Companies / BioTech

By: Money_Morning

Ernie Tremblay writes: The FDA's Expedited Programs help get promising new therapies for seriously ill patients approved as soon as possible.

But they also create an unintended side effect that's a huge advantage for investors: They point exactly to the biggest money-making opportunities in the bioscience industry.

Read full article... Read full article...

 


Companies

Wednesday, April 30, 2014

Biotech - New Melanoma Therapies Are Ready for Primetime / Companies / BioTech

By: TLSReport

Melanoma confronts patients and their physicians with unique barriers to treatment and successful outcomes. In this interview with The Life Sciences Report, Dr. Sanjiv Agarwala, chief of medical oncology and hematology at St. Luke's University Hospital, illuminates some of the new paradigms being developed in the treatment of this deadly skin cancer. Along the way, he spotlights interesting work in the field.

The Life Sciences Report: You have been a principal investigator in several different clinical trials exploring skin cancers and their metastatic manifestations. Because of your position at a major teaching institution, do you see mostly advanced-stage or late-stage patients? Are you ever able to see early-stage or treatment-naďve patients?

Read full article... Read full article...

 


Companies

Friday, April 25, 2014

Biotech Long-Term Profit Machines Stock Prices on Sale / Companies / BioTech

By: Money_Morning

Michael A. Robinson writes: Market volatility has suddenly created some great opportunities, including those in the biotech sector.

Supporting the inevitable ascent of the industry is the release of a steady stream of compounds that have helped them rack up billions in new revenue.

Consider that since it began trading in early 2001, the iShares Nasdaq Biotechnology Index (Nasdaq: IBB) is up 130%. That's more than triple the S&P 500's 13-year return of 43%.

Read full article... Read full article...

 


Companies

Friday, April 18, 2014

Build Biotech Wealth on Solid Platforms / Companies / BioTech

By: TLSReport

Potential. That's what every investor is looking for in a biotech investment. Grant Zeng of Zacks Small-Cap Research zeroes in on three primary factors when he looks at whether a particular company has the potential to succeed in the fast-moving life sciences industry. In this interview with The Life Sciences Report, Zeng dissects his process and names 10 companies that have survived his exacting examination.

The Life Sciences Report: As an analyst you focus on promising junior biotechs. What primary qualities do you look for in a company that you rate hold or outperform? And what do you think makes a junior biotech attractive to someone who might want to acquire it?

Read full article... Read full article...

 


Companies

Thursday, April 17, 2014

Hidden Australian Life Sciences Bio-tech Growth Stocks / Companies / BioTech

By: TLSReport

To find undiscovered stories, investors must venture into unfamiliar territory. In this interview with The Life Sciences Report, we go halfway around the world to speak with Scott Power of Morgans Financial Ltd. about companies under coverage in Australia. Power helps investors get comfortable with the idea of putting money into newfound names, and unveils four strong ideas that could invigorate adventuresome portfolios and investors hungering for excitement.

The Life Sciences Report: You are based in Brisbane, Australia, where your firm, Morgans Financial, is headquartered. All the names on your coverage list have traded on the Australian Securities Exchange (ASX). How would you compare investing in Australian biotech or medtech stocks to investing in those same types of stocks in the U.S. or Europe?

Read full article... Read full article...

 


Companies

Wednesday, April 16, 2014

There Is No Biotech Stock Bubble; Here's the Real Story / Companies / BioTech

By: Money_Morning

Ernie Tremblay writes: Some analysts feel that the biotech sector's recent tumble is evidence of the biotech bubble bursting.

But they're wrong; the market is simply in a period of adjustment.

The premise behind the bubble idea is that biotech companies as a group are overvalued, that their market caps aren't supported by performance. In other words, that their perceived value is all smoke and mirrors.

Read full article... Read full article...

 


Companies

Friday, April 11, 2014

Don't Miss the Boat on Big Biotech Catalysts: Keith Markey / Companies / BioTech

By: TLSReport

Keith Markey, veteran analyst and science director of Griffin Securities, tells us the 2014 pipeline calendar is positively glowing with important milestones that could ignite portfolios. In this interview with The Life Sciences Report, Markey talks about four powerful biotech names with exciting early- to late-stage development projects and one medical device and supply company with serious growth potential. Be warned—huge catalysts are on the horizon that investors won't want to miss.

Read full article... Read full article...

 


Companies

Monday, April 07, 2014

Biotech Investing - Finding the Blockbuster That Will Make You Rich / Companies / BioTech

By: Money_Morning

Ernie Tremblay writes: In the pharmaceutical industry, a "blockbuster" is any drug that brings in $1 billion or more in revenue per year.

It's the prize that every biotech hopes to win - and every biotech investor hopes to cash in on.

So how do you spot one in the making? If the market suspects a drug candidate has blockbuster potential, catalysts (events like positive clinical study results and regulatory milestones) will give its manufacturer's share price a big, big boost.

Read full article... Read full article...

 


Companies

Friday, February 28, 2014

Investors Should Evaluate Biotech Stocks with Cynicism / Companies / BioTech

By: TLSReport

Biotech investing is a risky business, so investors should thoroughly examine a company's vital statistics before taking the plunge. That's the recommendation of Managing Director Debjit Chattopadhyay of Emerging Growth Equities, who brings a strict scientific discipline to stock analysis. As a former medical researcher, Chattopadhyay comes by his skepticism honestly, and in this interview with The Life Sciences Report, he brings five exciting—but critically scrutinized—growth names to investors' attention.

Read full article... Read full article...

 


Commodities

Friday, February 14, 2014

Big Pharma Will Find Good Hunting Among Early-Stage Biotechs Stocks / Commodities / BioTech

By: TLSReport

Dhesh Govender, manager of the life sciences portfolio for Cedar Lane Enterprises Inc., has the inside track when it comes to identifying the hottest biotech trends. In this interview with The Life Sciences Report, Govender explains why he thinks plenty of upside remains in the life sciences sector, and reveals trade secrets that every investor should consider when building a successful investment strategy.

Read full article... Read full article...

 


Companies

Wednesday, February 12, 2014

Regenerative Medicine Finally Gets Some Respect / Companies / BioTech

By: TLSReport

Of the many themes that propelled the biotech sector to record returns in 2013, regenerative medicine and therapeutics targeting cancer were front and center. In this interview with The Life Sciences Report, Reni Benjamin, managing director and equity research analyst at H.C. Wainwright & Co., talks about two companies with impending catalysts that play on these themes, and offers his take on the prospects for the regenerative medicine sector going forward.

Read full article... Read full article...

 


Companies

Friday, January 17, 2014

New Way to Make Big Money in Biotech Stocks Sector / Companies / BioTech

By: Money_Morning

Ernie Tremblay writes: Traditional pharmaceutical blockbusters like Pfizer's Lipitor treat millions of patients at relatively low cost. It's a high-volume business model that has kept the pharmaceutical industry afloat for a long, long time. But over the past decade, out of necessity, a new model has taken the industry by storm.

As big moneymakers, like Lipitor, reach the "patent cliff," their intellectual rights protection are evaporating, and generic drug makers are taking over their markets.

Read full article... Read full article...

 


Stock-Markets

Sunday, January 05, 2014

Transformative Human Biotech Revolution Forecast 2014 / Stock-Markets / BioTech

By: John_Mauldin

It is that time of the year when we peer into our darkened crystal balls in hopes of seeing portents of the future in the shadowy mists. This year I see three distinct wisps of vapor coalescing in the coming years. Each deserves its own treatment, so this year the annual forecast issue will in fact be three separate weekly pieces.

The final letter of the series will discuss what I see as potentially developing in the markets this year, but such prognostication has to be framed within the context of two larger and far more important streams. Next week we will examine the larger economic problems facing much of the developed world, and specifically we'll consider the Era of Unfulfilled Expectations. What happens when governments and central banks find it impossible to live up to the promises that they have made to their constituencies? Throw in a mix of frustrating demographics and disastrous economic policy choices, and you have a witch's brew of uncertainties.

Read full article... Read full article...

 


Page << | 1 | 2 | 3 | 4 | 5 | 6 | 7 | >>